Celldex

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases.

CEO

Anthony S. Marucci

CEOAnthony S. Marucci

Employees

198

Employees198

Headquarters

Hampton, New Jersey

HeadquartersHampton, New Jersey

Founded

1983

Founded1983

Employees

198

Employees198

CLDX Key Statistics

Market cap

2.00B

Market cap2.00B

Price-Earnings ratio

-7.72

Price-Earnings ratio-7.72

Dividend yield

—

Dividend yield—

Average volume

1.24M

Average volume1.24M

High today

$30.69

High today$30.69

Low today

$29.62

Low today$29.62

Open price

$30.01

Open price$30.01

Volume

1.04M

Volume1.04M

52 Week high

$31.31

52 Week high$31.31

52 Week low

$14.40

52 Week low$14.40

Stock Snapshot

As of today, Celldex(CLDX) shares are valued at $30.00. The company's market cap stands at 2B, with a P/E ratio of -7.72.

During the trading session on 2026-03-02, Celldex(CLDX) shares reached a daily high of $30.69 and a low of $29.62. At a current price of $30.00, the stock is +1.3% higher than the low and still -2.2% under the high.

Trading activity shows a volume of 1.04M, compared to an average daily volume of 1.24M.

Over the past 52 weeks, Celldex(CLDX) stock has traded between a high of $31.31 and a low of $14.40.

CLDX News

TipRanks 14h

Celldex price target raised to $34 from $30 at Goldman Sachs

Goldman Sachs analyst Richard Law raised the firm’s price target on Celldex (CLDX) to $34 from $30 and keeps a Neutral rating on the shares. Celldex is entering...

TipRanks 1d

Celldex presents new data from Phase 2 ColdU, SD Open Label Extension

Celldex (CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension, highlighting that retreatment with barzolvolimab leads to rapid i...

Simply Wall St 2d

Assessing Celldex Therapeutics Valuation After Positive Barzolvolimab Phase 3 Enrollment And Phase 2 Data

Celldex Therapeutics (CLDX) has moved back into focus after completing enrollment ahead of schedule for its large Phase 3 barzolvolimab trials in chronic sponta...

Analyst ratings

81%

of 16 ratings

Buy

81.3%

Hold

12.5%

Sell

6.3%

More CLDX News

Nasdaq 4d

November 20th Options Now Available For Celldex Therapeutics

Investors in Celldex Therapeutics, Inc. (Symbol: CLDX) saw new options begin trading today, for the November 20th expiration. One of the key inputs that goes in...

Simply Wall St 5d

Celldex Therapeutics Is Up 34.0% After Completing Global Phase 3 Enrollment for Barzolvolimab in CSU - Has The Bull Case Changed?

Celldex Therapeutics recently announced it has completed enrollment of 1,939 patients across two global Phase 3 EMBARQ trials of barzolvolimab in chronic sponta...

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.